Georgetown University Neurology Clinical Research (GUNCR)

• HEALEY ALS Platform Trial
  • Study Coordinator: Gabby Law (gfl11@georgetown.edu)

• Radicava® (Edaravone) Findings in Biomarkers From ALS (REFINE-ALS)
  • Study Coordinator: Gabby Law (gfl11@georgetown.edu)

• Target ALS Biomarker Study; Longitudinal Biofluids, Clinical Measures, and At Home Measures (TALSLB)
  • Study Coordinator: Charlie Carpenter (cjc357@georgetown.edu)

• (MOVR) neuroMuscular ObserVational Research data hub
  • Study Coordinator: Gabby Law (gfl11@georgetown.edu)
• A Study to Assess the Safety, Tolerability, and Effect on Disease Progression of BIIB105 in Participants With Amyotrophic Lateral Sclerosis (ALS) and Participants With the ALS Ataxin-2 (ATXN2) Genetic Mutation (ALSpire)
  • Study Coordinator: Gabby Law (gfl11@georgetown.edu)

• Human Epilepsy Project 3 (HEP3)
  • Study Coordinator: Michelle Umali (mfu8@georgetown.edu)

• Registry of Subjects With Drug Resistant Epilepsy and Treated With the VNS Therapy System. (CORE-VNS)
  • Study Coordinator: Michelle Umali (mfu8@georgetown.edu)

• A Study to Evaluate the Safety of STS101 in the Acute Treatment of Migraine (ASCEND)
  • Study Coordinator: Charlie Carpenter (cjc357@georgetown.edu)

• An Open-Label, Multiple-Dose Evaluation of the Efficacy and Safety of AXS-07 (meloxicam and rizatriptan) for the Acute Treatment of Migraine in Adults with a Prior Inadequate Response to an Oral CGRP Inhibitor (Axsome AXS-07-304)
  • Study Coordinator: Charlie Carpenter (cjc357@georgetown.edu)

• Preventive Treatment of migraine: Outcomes for Patients in real-world Healthcare systems (TRIUMPH)
  • Study Coordinator: Charlie Carpenter (cjc357@georgetown.edu)

• A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (O’HAND)
  • Study Coordinator: Daniel Bustamante (db1621@georgetown.edu)

• Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Teriflunomide In Relapsing Multiple Sclerosis (RMS) (FENhance) (GN42272)
  • Study Coordinator: Nikta Najib (nn358@georgetown.edu)

• Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial (TREAT-MS)
  • Study Coordinator: David Pisfil (ddp39@georgetown.edu)
• The MS-LINK™ Outcomes Study
  • Study Coordinator: Aastha Bhatnagar (ab4004@georgetown.edu)

• A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Patients With Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (Meteoroid)
  • Study Coordinator: Nikta Najib (nn358@georgetown.edu (new window))

• CorEvitas SPHERES (Synergy of Prospective Health & Experimental Research for Emerging Solutions) Registry for Neuromyelitis Optica Spectrum Disorder (NMOSD)
  • Study Coordinator: Daniel Bustamante (db1621@georgetown.edu (new window))

• A Study to Investigate the Efficacy and Safety of NT 201 (Botulinum Toxin) Compared With Placebo for the Treatment of Adult Participants With Essential Tremor in the Arm
  • Study Coordinator: Luke Lovelace (ll928@georgetown.edu (new window))

• Product Surveillance Registry (PSR)
  • Study Coordinator: David Pisfil (ddp39@georgetown.edu (new window))

• PROSEEK: A Phase 2 Study In Early Parkinson’s Disease Patients Evaluating The Safety And Efficacy Of Abl Tyrosine Kinase Inhibition Using K0706 (CLR_18_06 / PROSEEK)
  • Study Coordinator: Luke Lovelace (ll928@georgetown.edu (new window))

• Study to Assess How ABBV-951 is Absorbed When Administered at Different Subcutaneous Sites of Adult Participants With Parkinson’s Disease
  • Study Coordinator: Luke Lovelace (ll928@georgetown.edu (new window))

• Acute Stroke Program of Interventions Addressing Racial and Ethnic Disparities (ASPIRE)
  • Study Coordinator: Michelle Umali (mfu8@georgetown.edu)

• A Safety and Efficacy Study of Intravenous (IV) Elezanumab Assessing Change in Neurologic Function in Adult Participants With Acute Ischemic Stroke (M19-148 / EAISE)
  • Study Coordinator: Michelle Umali (mfu8@georgetown.edu)

• AtRial Cardiopathy and Antithrombotic Drugs In Prevention After Cryptogenic Stroke (ARCADIA)

Study Coordinator: Michelle Umali (mfu8@georgetown.edu)